sexta-feira, 22 de novembro de 2019
terça-feira, 19 de novembro de 2019
CRITÉRIOS PARA ESTUDO DE VIABILIDADE (estudo piloto)
Em estudos de viabilidade, os critérios
de viabilidade se tornam primários e os demais desfechos (estudo propriamente
dito) passam a ser analisados como secundários). Assim, o foco é o entendimento
da viabilidade de realização do estudo completo.
Feasibility outcomes
1.
Blinding of assessor - Assessor’s correct guess for group allocation
2.
Attrition rate (in both arms) - Acceptability of random allocation to a
treatment group
3.
Contamination of intervention - Understanding possible contamination between
the groups
a. Have you talked to other
participants in this study about the intervention they are receiving?
b. Has your attitude towards the
intervention changed after talking to the participant (s) in the other group?
c. Are any of the participants in the
other group aware of the type of intervention you are receiving in this study?
4.
Adherence to treatment - Adherence to treatment
a. n
b. Number of days (SD)
5.
Satisfaction
(all the participants of the Intervention group will be asked to respond an
adapted version of the MedRisk Instrument for Measuring Patient Satisfaction with
Physical Therapy Care (MRPS)56 at 1 week following treatment). The question
asked will be:
a. Did my physiotherapist carefully
explain the treatments I received?
b. Did my physiotherapist treat me
respectfully?
c. Did my physiotherapist answer all my
questions? Responses to this question are made on a five points categorical scale
i.
1=
‘completely disagree’
ii.
2=
‘Disagree’
iii.
3=
‘Neutral’
iv.
4=
‘Agree’
v.
5=
‘Completely agree’
6.
Difficulty scale - Difficulty in understanding the information provided by the
physiotherapist. Responses to this question are made on a five points
categorical scale
a. Very easy
b. Easy
c. Neither easy nor difficult
d. Difficult
e. Very difficult
Referências importantes para
estudos de viabilidade (estudo piloto):
Thabane L, Ma J, Chu R, et al. A tutorial on pilot studies: the
what, why and how. BMC Med Res Methodol. 2010;10:1.
doi:10.1186/1471-2288-10-1.
Chan A-W, Tetzlaff JM, Gøtzsche PC, et al.
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical
trials. BMJ. 2013;346:e7586. doi:10.1136/BMJ.E7586.
Eldridge SM, Chan CL, Campbell MJ, et al.
CONSORT 2010 statement: extension to randomised pilot and feasibility trials. BMJ.
2016;355:i5239. doi:10.1136/BMJ.I5239.
Billingham SA, Whitehead AL, Julious SA. An
audit of sample sizes for pilot and feasibility trials being undertaken in the
United Kingdom registered in the United Kingdom Clinical Research Network
database. BMC Med Res Methodol. 2013;13(1):104.
doi:10.1186/1471-2288-13-104.
Fergusson D. Turning a blind eye: the success
of blinding reported in a random sample of randomised, placebo controlled
trials. BMJ. 2004;328(7437):432-0. doi:10.1136/bmj.37952.631667.EE.
Schulz KF, Grimes DA. Blinding in randomised
trials: Hiding who got what. Lancet. 2002;359(9307):696-700.
doi:10.1016/S0140-6736(02)07816-9.
McGrath JM. Not all studies with small samples
are pilot studies. J Perinat Neonatal Nurs. 27(4):281-283.
doi:10.1097/01.JPN.0000437186.01731.bc
Assinar:
Postagens (Atom)